Biovaxys Technology Corp Stock Profit Margin
| BVAXF Stock | USD 0.05 0 2.95% |
Biovaxys Technology Corp fundamentals help investors to digest information that contributes to Biovaxys Technology's financial success or failures. It also enables traders to predict the movement of Biovaxys OTC Stock. The fundamental analysis module provides a way to measure Biovaxys Technology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biovaxys Technology otc stock.
Biovaxys |
Biovaxys Technology Corp OTC Stock Profit Margin Analysis
Biovaxys Technology's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Biovaxys Technology Corp has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Biovaxys Fundamentals
| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 11.35 M | |||
| Shares Outstanding | 106.72 M | |||
| Shares Owned By Insiders | 18.94 % | |||
| Price To Earning | (4.32) X | |||
| Price To Book | 2.53 X | |||
| EBITDA | (6.44 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 39.05 K | |||
| Current Ratio | 0.16 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (5.29 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 17 | |||
| Beta | -0.59 | |||
| Market Capitalization | 8.73 M | |||
| Total Asset | 8.5 M | |||
| Retained Earnings | (80 M) | |||
| Working Capital | 35 M | |||
| Current Asset | 37 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -7.8 | |||
| Net Asset | 8.5 M |
About Biovaxys Technology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biovaxys Technology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovaxys Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovaxys Technology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.